Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1511-1517

  Kelsen, D P ^a   Martin, D ^a   O'Neil, J ^a   Schwartz, G ^a   Saltz, L ^a   Sung, M T ^a   von Borstel, R ^a   Bertino, J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PN 401; PRODRUG; UNCLASSIFIED DRUG; URIDINE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; APPENDIX CANCER; ARTICLE; BILE DUCT CANCER; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; STOMACH CANCER; SUSPENSION; TABLET;

EID: 0030958101     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1511     Document Type: Article

References (14)

1. Pinedo HM, Peters GFJ: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988
2. Martin DS, Stolfi RL, Sawyer RC, et al: High-dose 5-fluorouracil with delayed uridine "rescue" in mice. Cancer Res 42:3964-3970, 1982
3. Klubes P, Cerna I, Meldon MA: Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol 8:17-21, 1982
4. Peters GJ, vanDijk J, Laurensse E, et al: In vitro biochemical and in vivo biological studies of the uridine rescue of 5-fluorouracil. Br J Cancer 57:259-265, 1988
5. Martin DS, Stolfi RL, Sawyer RC: Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 24:9-14, 1989
6. Klubes P, Leyland-Jones B: Enhancement of the antitumor activity of 5-fluorouracil by uridine rescue. Pharmacol Ther 41:289-302, 1989
7. Nord LD, Stolfi RL, Martin DS: Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue. Correlation of anti-tumor activity with dosage and FUra incorporation into RNA. Biochem Pharmacol 43:2543-2549, 1992
8. Leyva A, van Groeningen CJ, Kraal I, et al: Phase I and pharmacokinetic studies of high-dose undine intended for rescue from 5-fluorouracil toxicity. Cancer Res 44:5928-5933, 1984
9. van Groeningen CJ, Leyva A, Kraal I, et al: Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 70:745-750, 1986
10. van Groeningen CJ, Peters GJ, Nodal JC, et al: Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 83:437-441, 1991
11. Seiter K, Kemeny N, Martin D, et al: Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. Cancer 71:1875-1881, 1993
12. Schwartz GK, Christman K, Saltz L, et al: A phase I trial of a modified intensive FAMTX regimen (high dose 5-fluorouracil + doxorubicin + high dose metotrexate + leucovorin) with oral uridine rescue. Cancer (in press)
13. Fraile R, Baker L, Buroker T, et al: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40:2223-2228, 1980
14. Schwartz PM, Turek PJ, Hyde CM, et al: Altered plasma kinetics of 5-FU at high dosage in rat and man. Cancer Treat Rep 69:133-136, 1985